BANK VONTOBEL/CALL/EDWARDS LIFESCIENCES/84/0.1/20.12.24

BANK VONTOBEL/CALL/EDWARDS LIFESCIENCES/84/0.1/20.12.24 Stock

DE000VD5RXN7

Real-time Boerse Frankfurt Warrants 08:04:24 2024-07-02 EDT
1.15 ^EUR	-1.71%

Current month	-13.97%
1 month	+24.47%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart EDWARDS LIFESCIENCES CORPORATION

Chart BANK VONTOBEL/CALL/EDWARDS LIFESCIENCES/84/0.1/20.12.24

Latest news about EDWARDS LIFESCIENCES CORPORATION

Evercore ISI Adjusts Price Target on Edwards Lifesciences to $91 From $89, Maintains In-line Rating	08:11am	MT
Edwards Lifesciences Insider Sold Shares Worth $492,258, According to a Recent SEC Filing	06-20	MT
Edwards Lifesciences Corporation Announces Executive Changes	06-17	CI
Wolfe Research Adjusts Price Target on Edwards Lifesciences to $70 From $75	06-17	MT

More news

Quotes 5-day view

Date	Price	Change
24-07-02	1.15	-1.71%
24-07-01	1.17	-13.97%
24-06-28	1.36	-2.86%
24-06-27	1.4	+12.00%
24-06-26	1.25	+4.17%

Real-time Boerse Frankfurt Warrants

Last update July 02, 2024 at 08:04 am

More quotes

Static data

Product type	Warrants
Buy / Sell	CALL
Underlying	EDWARDS LIFESCIENCES CORPORATION
Issuer	Vontobel
WKN	VD5RXN
ISIN	DE000VD5RXN7
Date issued	2024-05-07
Strike	84 $
Maturity	2024-12-20 (171 Days)
Parity	10 : 1
Emission price	0.92 €
Emission volume	N/A
Settlement	règlement en espèces
Currency	EUR

Technical Indicators

Highest since issue	1.41 €
Lowest since issue	0.91 €
Delta	0x
Omega	0.000000
Premium	0x
Gearing	11.02x
Moneyness	1.659
Difference Strike	-6.25 $
Difference Strike %	-7.44%
Spread	0.06 €
Spread %	4.96%
Intrinsic value	5.163
Present value	-4.002885

Company Profile

Edwards Lifesciences Corporation specializes in designing, manufacturing and marketing medical systems and devices for treating cardiovascular diseases. Net sales break down by family of products as follows: - heart valves and surgery products (67.9%); - hemodynamic monitoring systems (15.5%); - other (16.6%): balloon catheters, artificial implants, etc. Net sales are distributed geographically as follows: the United States (58.4%), Europe (22.2%), Japan (7.6%) and other (11.8%).

Sector

More about the company